Clinical Disposable Blood Collection Tube Market Overview
clinical disposable blood collection tube market size was valued at USD 123242.98 million in 2025 and is poised to grow from USD 125954.33 million in 2026 to USD 184740.94 million by 2035, growing at a CAGR of 2.2% during the forecast period (2026-2035).
The clinical disposable blood collection tube market is supported by the essential role of standardized specimen collection in routine diagnostics, chronic disease monitoring, preventive screening, transfusion services, and specialized laboratory testing. Blood collection tubes are designed to preserve specimen quality between venipuncture and analysis, with material selection, additive compatibility, closure integrity, vacuum performance, and labeling accuracy influencing laboratory reliability. Plastic tubes are gaining preference in many high-volume settings because they are lighter and less prone to breakage than glass, while glass formats retain relevance where chemical compatibility, dimensional stability, or established laboratory protocols favor their use. More than 85% of routine laboratory blood tests depend on collected blood specimens, underscoring the importance of dependable single-use collection systems across medical centers and blood centers. Demand is also being shaped by laboratory automation, barcode-based identification, stricter infection-prevention practices, and the need to reduce pre-analytical errors across increasingly centralized testing networks.
In the United States, demand is influenced by high diagnostic testing intensity, established hospital laboratory networks, blood donation services, and regulatory expectations for medical-device quality. Clinical laboratories process large volumes of specimens across chemistry, hematology, coagulation, immunology, and blood-bank workflows, creating sustained requirements for tubes with consistent draw volumes and validated additives. Product changes and regulatory clearances remain important: during 2024, multiple BD Vacutainer tube configurations underwent labeling, instructions-for-use, and product-array updates, while a new 10.0 mL serum separator tube configuration became available in September 2024. The FDA also issued a substantial-equivalence decision for BD Vacutainer Citrate Blood Collection Tubes on October 31, 2024. These developments illustrate how product lifecycle management, traceability, and documentation influence procurement decisions in a market where even small changes in tube dimensions, additives, or labeling can affect established laboratory procedures.
Download Free sample to learn more about this report.
Key Findings
- Leading Product Type: Plastic Tube is expected to lead material demand, accounting for an estimated 63% share in 2026 as lower breakage risk, reduced weight, and compatibility with high-throughput laboratory handling support broader adoption.
- Leading Application: Medical Center is projected to represent approximately 76% of application demand in 2026, reflecting its broad mix of routine diagnostics, emergency testing, inpatient monitoring, and outpatient specimen collection.
- Leading Region: Asia-Pacific is estimated to hold 36% of global demand in 2026, supported by expanding diagnostic access, large patient populations, and growing hospital and laboratory capacity across major economies.
- Fastest Growing Region: Asia-Pacific is projected to record an indicative 3.1% CAGR through 2035 as laboratory infrastructure investment and preventive screening programs widen access to routine blood testing.
- Technology Trend: Rapid-serum processing is gaining attention, with RAPClot tube technology designed to produce high-quality serum in approximately 5 minutes, potentially shortening selected laboratory preparation workflows.
- Market Driver: The scale of diagnostic testing remains a central demand driver, with blood specimens supporting more than 85% of routine laboratory tests and sustaining recurring requirements for sterile collection tubes.
- Competitive Landscape: Product portfolio refinement remains active, illustrated by BD's 2024 introduction of a 10.0 mL serum separator tube configuration and multiple associated labeling and instructions-for-use updates.
- Future Outlook: Material optimization and faster specimen processing are expected to shape product development, while the supplied market forecast indicates a 2.2% CAGR over the 2026–2035 period.
Latest Trends
Material substitution is one of the most visible trends in the clinical disposable blood collection tube market. Plastic formats are increasingly selected for high-volume collection because they reduce breakage exposure during transport, centrifugation, sorting, and automated laboratory handling. An industry estimate places plastic at approximately 55% of the broader blood collection tube market in 2025, reflecting its established position in routine specimen workflows. Glass tubes continue to serve applications where laboratories value chemical resistance, dimensional consistency, or compatibility with long-standing analytical procedures. Manufacturers are therefore not moving toward a single universal material; instead, they are refining product portfolios around test requirements, sample stability, transport conditions, and the operating characteristics of laboratory equipment. This differentiated approach is especially important in medical centers processing thousands of samples daily, where small reductions in breakage, leakage, or specimen rejection can produce meaningful operational benefits.
Another trend is the convergence of tube design with faster processing, digital identification, and automated laboratory systems. Barcode-ready labels, standardized dimensions, consistent vacuum performance, and improved additive formulations help laboratories manage specimen identity and reduce manual handling across multi-stage workflows. In February 2026, Terumo's Japanese partner launch of VenoJect II RAPClot evacuated blood collection tubes brought rapid-serum technology into a commercial market, with the technology designed to produce serum in about 5 minutes. The development reflects interest in shortening the interval between collection and analysis without compromising specimen quality. At the same time, manufacturers are refining instructions for use, product coding, and labeling to support traceability and regulatory compliance. As centralized laboratories and blood centers expand automated processing, tubes that combine reliable specimen preservation with predictable machine compatibility are likely to attract greater procurement attention.
Market Dynamics
Driver
""Growing diagnostic testing volumes sustain recurring demand for dependable specimen collection.""
Increasing demand for clinical diagnostics is the primary structural driver for disposable blood collection tubes. Blood specimens are used in routine chemistry panels, complete blood counts, coagulation tests, infectious disease screening, hormone analysis, therapeutic drug monitoring, and numerous specialized investigations. More than 85% of routine laboratory blood tests rely on blood specimens, making collection tubes a recurring consumable rather than an occasional capital purchase. Every patient sample requires a container compatible with the intended test, and a single clinical visit may involve multiple tubes containing different additives or designed for separate analytical workflows. This creates a dependable replacement cycle across medical centers and blood centers, even when broader healthcare procurement budgets fluctuate.
The growing burden of non-communicable diseases further strengthens this demand base. Diabetes, cardiovascular disease, kidney disorders, and cancer frequently require repeated laboratory monitoring for diagnosis, treatment selection, and follow-up. The International Diabetes Federation estimated that 589 million adults aged 20–79 were living with diabetes worldwide in 2024, illustrating the scale of conditions that generate ongoing blood-testing needs. As screening programs expand and clinical guidelines encourage earlier detection, the number of specimens handled by laboratories can rise even without a proportional increase in hospital admissions. Blood collection tubes therefore benefit from both acute-care testing and longitudinal monitoring, with medical centers serving as the largest demand channel in this report's application analysis.
Restraint
""Price pressure and strict quality requirements limit margin flexibility.""
Price competition is a persistent restraint because many disposable blood collection tubes are purchased in high volumes through tenders, distributor contracts, and centralized hospital procurement. Standard tubes can appear interchangeable to buyers, encouraging comparisons based on per-unit cost and delivery terms. This can place pressure on manufacturers, particularly when raw-material costs, energy expenses, sterilization requirements, packaging, and transportation costs increase. Suppliers must maintain validated production processes while competing with lower-priced alternatives, making it difficult to pass every cost increase to customers. The challenge is particularly relevant in emerging markets, where public healthcare budgets and diagnostic laboratory spending may be constrained despite rising testing volumes.
Regulatory and quality requirements create an additional cost burden. Blood collection tubes are medical devices whose performance depends on material quality, sterility, vacuum consistency, additive concentration, closure integrity, and specimen compatibility. Manufacturers must maintain documented quality systems, conduct product verification, manage changes to labeling and instructions for use, and meet applicable market-specific regulatory requirements. In the United States, FDA 510(k) decisions are part of the regulatory pathway for relevant tube products; BD Vacutainer Citrate Blood Collection Tubes received a substantial-equivalence decision on October 31, 2024. Such requirements protect users and patients, but they can extend development timelines and increase compliance expenses, especially for companies seeking to enter several international markets.
Opportunity
""Expanding diagnostic access creates room for localized production and product differentiation.""
Expansion of diagnostic infrastructure across emerging economies offers a substantial opportunity for clinical disposable blood collection tube manufacturers. New medical centers, regional laboratories, community screening programs, and blood service facilities require reliable supplies of sterile collection consumables as they broaden test menus and patient coverage. Asia-Pacific is particularly important because it combines large populations with ongoing investment in public hospitals, private diagnostic chains, and centralized laboratory networks. An estimated 36% regional share in 2026 reflects its scale in this analysis, while an indicative 3.1% CAGR through 2035 points to further growth potential. Suppliers able to provide consistent quality at competitive prices, maintain local distribution, and support regulatory documentation can improve their position in markets where procurement increasingly considers both cost and supply continuity.
Product differentiation is another opportunity, particularly in tubes designed to improve specimen stability, reduce processing time, and support specialized testing. The February 2026 commercial introduction in Japan of VenoJect II RAPClot evacuated tubes demonstrates the market interest in rapid-serum technology, with the system designed to produce high-quality serum in approximately 5 minutes. While adoption will depend on validation for specific laboratory workflows, faster preparation could be attractive to facilities seeking shorter turnaround times. Manufacturers can also differentiate through improved cap designs, lower dead volume, optimized additives, more durable labels, and formats that fit automated analyzers. These refinements may be commercially meaningful even when the basic tube architecture remains familiar.
Challenge
""Maintaining sample integrity across diverse workflows remains a demanding technical task.""
A central challenge is ensuring that every tube preserves the intended specimen characteristics from collection through laboratory analysis. Different tests require different additives, fill volumes, mixing procedures, and processing conditions. A tube intended for anticoagulated whole blood cannot automatically replace a serum tube, while coagulation testing can be sensitive to the ratio between blood volume and anticoagulant. Underfilling, overfilling, inadequate mixing, or incorrect tube selection can affect analytical results. These risks become more complex in facilities that process many test categories and use multiple analyzer platforms. Manufacturers must therefore provide clear product identification and instructions, while medical centers must train staff to follow collection order, fill-level, and handling protocols consistently.
Maintaining reliable performance across production batches is another significant challenge. Disposable tubes require tight control over dimensions, wall thickness, vacuum level, additive quantity, closure fit, and sterilization or cleanliness parameters, depending on the product design. Even minor deviations can influence draw volume, leakage risk, specimen stability, or compatibility with automated equipment. High-volume manufacturing requires process controls that can detect defects before products reach clinical users. Suppliers also need robust packaging and transportation systems because tubes may travel through long distribution networks and experience changes in temperature, humidity, and handling conditions. These demands can be especially difficult for manufacturers serving multiple markets with different regulatory and labeling requirements.
Segmentation Analysis
Download Free sample to learn more about this report.
By Types
Plastic Tube: Plastic Tube is estimated to account for 63% of the clinical disposable blood collection tube market in 2026, making it the leading product type in this analysis. Its position is supported by lower breakage risk, lighter weight, ease of handling, and suitability for high-volume transport and automated laboratory workflows. Plastic formats are widely used where tubes move through pneumatic transport systems, centrifuges, barcode scanners, and automated sample-processing equipment. Their resistance to shattering can reduce handling hazards and specimen loss, particularly in busy medical centers processing hundreds or thousands of samples per shift. Manufacturers continue to refine polymer selection, wall consistency, closure systems, and surface characteristics to improve performance across different specimen types. Plastic tubes are also attractive for large procurement programs because their lower weight can simplify packaging and distribution. However, product selection still depends on the intended test, additive compatibility, temperature exposure, and validated analyzer requirements. The estimated 63% share reflects the broad operational advantages of plastic rather than a claim that it is suitable for every clinical test.
Glass Tube: Glass Tube is estimated to represent 37% of the market in 2026. Glass remains relevant in laboratories that value its chemical resistance, dimensional stability, and established compatibility with selected analytical procedures. It can be appropriate where a particular test method or laboratory protocol has been validated around glass containers, and some users prefer its surface characteristics for specific specimen-handling requirements. Glass also provides a familiar format in facilities with long-standing workflows and equipment designed around conventional tube dimensions. Nevertheless, its greater weight and susceptibility to breakage can create disadvantages during collection, transport, centrifugation, and disposal. These considerations have encouraged many high-throughput facilities to prioritize plastic for routine collection, while retaining glass for selected applications. Suppliers serving this segment must focus on consistent wall thickness, controlled dimensions, reliable closures, and safe packaging. The 37% estimated share recognizes the continued use of glass in specialized and established workflows, even as plastic maintains the larger position in the overall material mix.
By Applications
Medical Center: Medical Center is estimated to account for 76% of application demand in 2026, reflecting its broad role in inpatient, outpatient, emergency, surgical, and preventive diagnostic services. Hospitals and affiliated medical facilities collect blood for chemistry panels, hematology, coagulation, infectious disease screening, blood grouping, therapeutic monitoring, and pre-operative assessment. A single patient encounter can require multiple tubes because different tests may need serum, plasma, or whole blood prepared with specific additives. The segment benefits from recurring patient monitoring, chronic disease management, and the expansion of hospital-based diagnostic capabilities. Large medical centers also tend to use standardized procurement contracts and automated laboratory systems, increasing demand for tubes with consistent dimensions, reliable vacuum performance, and machine-readable labels. The estimated 76% share reflects the concentration of diverse blood collection activities in these institutions. Their purchasing decisions increasingly weigh total workflow cost, specimen rejection risk, product consistency, and uninterrupted supply, rather than relying solely on the lowest unit price.
Blood Center: Blood Center is estimated to account for 24% of application demand in 2026. These facilities support donor screening, blood grouping, compatibility testing, infectious disease testing, and other laboratory procedures required to assess donated blood and support transfusion services. Their tube requirements are shaped by high-volume, repeatable workflows where specimen identification and traceability are critical. Accurate labeling and secure closure systems help maintain the link between donor records, collected samples, test results, and blood components. Blood centers also require dependable supply planning because interruptions can affect testing schedules and the availability of screened blood products. The segment is supported by the global scale of blood donation, with approximately 118.5 million donations collected annually according to a widely cited WHO estimate. That figure describes the wider donation ecosystem rather than the number of disposable tubes consumed. The 24% share in this analysis reflects the focused but essential role of blood centers alongside the broader and more varied specimen collection activity conducted by medical centers.
Regional Outlook
Download Free sampleto learn more about this report.
Asia-Pacific
Asia-Pacific is estimated to hold 36% of the clinical disposable blood collection tube market in 2026, making it the leading regional market in this analysis. Its position reflects the scale of healthcare demand across China, India, Japan, South Korea, and Southeast Asian economies, together with expanding diagnostic laboratory networks and investment in hospital infrastructure. Large populations and a growing burden of chronic conditions create sustained requirements for routine blood testing, while preventive screening and wider access to private diagnostics are increasing specimen collection in urban and semi-urban locations. Regional manufacturers also contribute to supply availability by serving domestic procurement programs and supplying standardized consumables to neighboring markets. The combination of local manufacturing capacity, broad distribution networks, and rising laboratory throughput supports Asia-Pacific's leading share.
Growth across Asia-Pacific is expected to remain comparatively strong, with an indicative CAGR of 3.1% through 2035. Investment in diagnostic infrastructure, public health screening, and hospital modernization is likely to support incremental demand for both Plastic Tube and Glass Tube formats. Plastic products are expected to gain from their lower breakage risk and suitability for automated sample handling, while glass formats will remain relevant in laboratories with established protocols or specific compatibility requirements. Procurement conditions differ significantly across the region: large urban hospitals may prioritize automation compatibility and traceability, whereas smaller facilities may place greater emphasis on affordability and reliable distribution. Suppliers that can balance cost, quality, and local regulatory requirements are positioned to benefit from the region's broadening diagnostic base.
North America
North America is estimated to account for 27% of global demand in 2026. The region benefits from mature hospital systems, established clinical laboratory networks, high diagnostic testing intensity, and well-developed blood collection services. The United States represents the largest national market within the region, supported by extensive use of laboratory testing in preventive care, chronic disease management, emergency medicine, and specialized treatment pathways. Standardized collection protocols and the presence of large reference laboratories encourage demand for tubes with predictable draw volumes, consistent additives, and reliable barcode labeling. Procurement teams also place considerable emphasis on product documentation, regulatory status, quality assurance, and compatibility with automated laboratory equipment.
North American demand is expected to be steady through 2035, with replacement purchasing and ongoing product refinement supporting the market. Regulatory activity illustrates the importance of lifecycle management: BD Vacutainer Citrate Blood Collection Tubes received an FDA substantial-equivalence decision on October 31, 2024, while BD also communicated product and labeling changes for its serum separator tube range during 2024. These developments demonstrate the role of regulatory review, updated instructions for use, and controlled product transitions in maintaining established laboratory supply relationships. Suppliers compete through portfolio breadth, quality consistency, distribution reliability, and service support. Although procurement consolidation can intensify price pressure, the region's advanced diagnostic infrastructure sustains demand for dependable disposable collection products.
Europe
Europe is estimated to represent 24% of the clinical disposable blood collection tube market in 2026. Demand is supported by extensive public healthcare coverage in many countries, established hospital laboratories, national screening programs, and a strong network of diagnostic and transfusion services. Germany, France, the United Kingdom, Italy, and other major markets maintain significant requirements for routine and specialized blood testing. The region's laboratories place importance on specimen quality, product traceability, and compliance with medical-device requirements. Standardized procedures across large healthcare systems also support demand for tubes with consistent dimensions, dependable closures, and clearly differentiated additives. Both Glass Tube and Plastic Tube formats remain relevant, although the balance varies according to local procurement standards and laboratory equipment.
European market development is expected to emphasize product reliability, sustainable procurement, and efficient laboratory workflows. Environmental considerations are increasingly relevant because single-use medical consumables generate waste that must be managed under healthcare-specific safety procedures. Manufacturers are therefore encouraged to optimize packaging, reduce unnecessary material use, and assess the lifecycle impact of products without compromising sterility or specimen integrity. Automation in larger laboratories is also increasing the value of tubes with machine-readable labels and consistent physical specifications. Competition is shaped by established international suppliers and regional manufacturers, while healthcare procurement frameworks can favor suppliers able to demonstrate quality assurance, stable delivery, and compliance across multiple countries. Europe's estimated 24% share reflects its mature diagnostic base and continued need for standardized specimen collection.
Latin America
Latin America is estimated to hold 7% of global market demand in 2026. Brazil and Mexico are important contributors because of their large populations, hospital networks, private diagnostic laboratories, and blood service infrastructure. Demand is supported by routine clinical testing, maternal and child health services, infectious disease screening, and monitoring of chronic conditions. However, purchasing patterns vary between major metropolitan healthcare systems and smaller facilities where budgets and distribution access can be more constrained. Public procurement programs and private laboratory chains both influence product selection, with price, dependable availability, and quality documentation remaining important considerations. Plastic tubes are attractive for many high-volume workflows because of their reduced breakage risk, while glass formats continue to serve selected laboratory requirements.
Market expansion in Latin America will depend on improved access to diagnostic services, consistent supply chains, and investment in laboratory capacity. Import dependence for selected medical consumables can expose buyers to currency movements, freight costs, and longer replenishment cycles. Local distributors therefore play an important role in ensuring that medical centers and blood centers receive products in the correct sizes and configurations. Manufacturers that establish reliable regional partnerships and maintain a competitive product mix may be better positioned to win institutional contracts. Growth in preventive screening and chronic disease monitoring should support recurring demand, although economic volatility and differences in healthcare funding are likely to moderate the pace of expansion. The estimated 7% share reflects the region's developing but meaningful role in global tube consumption.
Middle East & Africa
The Middle East & Africa region is estimated to account for 6% of the market in 2026. Demand is concentrated in countries with expanding hospital capacity, established private healthcare providers, national screening initiatives, and organized blood transfusion services. Gulf Cooperation Council markets are investing in modern hospitals and diagnostic infrastructure, while several African countries are working to strengthen laboratory access and blood safety systems. These developments create requirements for sterile disposable collection tubes across routine testing, donor screening, and specialized clinical investigations. Procurement conditions differ considerably, with advanced urban facilities often requiring broad product portfolios and smaller or remote centers facing challenges related to affordability, storage, and distribution continuity.
The region's outlook is supported by healthcare infrastructure development and the need to strengthen diagnostic and transfusion services, but supply reliability remains a key challenge. Import logistics, customs procedures, currency volatility, and uneven distribution networks can affect availability and final procurement costs. Suppliers may find opportunities through regional distributors, public-sector tenders, and partnerships with hospital groups, provided they can maintain consistent quality and appropriate regulatory documentation. Product education is also important because correct tube selection, fill volume, and handling practices influence the reliability of laboratory results. The estimated 6% share reflects the region's current scale while recognizing the potential for gradual expansion as diagnostic access and institutional capacity improve.
List of Top Clinical Disposable Blood Collection Tube Companies
- Sarstedt
- TUD
- Hongyu Medical
- Medtronic
- BD
- Sanli
- GBO
- Terumo
- Gong Dong
- CDRIC
Top 2 Companies Market Share
BD: BD is a major participant in the clinical disposable blood collection tube market through its Vacutainer portfolio, which includes serum separator, citrate, fluoride, EDTA, and heparin tube configurations. Its competitive position is supported by an established global distribution network, a broad range of tube sizes, and long-standing relationships with hospitals, medical centers, and clinical laboratories. During 2024, BD communicated updates involving its serum separator tube product array, electronic instructions for use, and labeling, including the availability of a 10.0 mL SST configuration in September. Its citrate blood collection tubes also received an FDA substantial-equivalence decision in October 2024. These activities illustrate the importance of regulatory maintenance and portfolio continuity in a market where laboratories depend on validated collection products. BD's individual market share is not stated because a reliable, directly comparable company-level percentage is not available.
Sarstedt: Sarstedt is an established supplier of laboratory and medical consumables, including blood collection systems designed for specimen collection, transport, and processing. Its competitive relevance is supported by a broad product portfolio and experience serving clinical laboratories, hospitals, and healthcare institutions across international markets. In the disposable tube category, product consistency, compatibility with laboratory procedures, and dependable supply are important factors in maintaining customer relationships. The company competes in an environment where buyers assess tube performance alongside packaging, labeling, additive suitability, and compatibility with automated workflows. Sarstedt's ability to serve different laboratory requirements supports its position among the prominent suppliers identified for this market. No specific company-level share is assigned because comparable verified market-share figures for the listed manufacturers are not publicly established.
Investment Analysis
Investment in the clinical disposable blood collection tube market is increasingly directed toward manufacturing consistency, quality systems, automation compatibility, and product differentiation. Because tubes are recurring consumables used across routine diagnostics and blood services, suppliers can benefit from repeat purchasing when they maintain reliable quality and distribution. Investment in automated inspection, controlled additive dispensing, vacuum calibration, closure integrity testing, and barcode-ready labeling can help manufacturers reduce production variability and meet the requirements of high-throughput laboratories. The market's supplied forecast indicates a 2.2% CAGR from 2026 to 2035, suggesting that investment strategies are likely to focus on operational efficiency, market penetration, and specialized product improvements rather than relying exclusively on rapid volume expansion.
Regional manufacturing and distribution capabilities are also important investment priorities. Asia-Pacific represents an estimated 36% of the market in 2026, making local production, supplier partnerships, and distribution coverage particularly relevant for companies seeking to serve its large diagnostic base. North America and Europe, with estimated shares of 27% and 24% respectively, remain important markets for suppliers able to meet demanding quality, documentation, and regulatory expectations. Investment in product registration, technical support, inventory management, and validated packaging can help reduce supply interruptions across these regions. Companies may also evaluate opportunities in blood center supply chains, where reliable identification and specimen traceability are essential. A balanced investment approach that combines cost-efficient production with quality assurance and regional availability is likely to be more resilient than expansion based only on manufacturing capacity.
New Product Development
New product development is increasingly focused on improving the interval between specimen collection and laboratory analysis while preserving sample quality. Rapid-serum technology is one example of this direction. In February 2026, Terumo introduced VenoJect II RAPClot blood collection tubes in Japan using Q-Sera's patented technology, which is designed to produce high-quality serum in approximately 5 minutes, including from anticoagulated samples. This development demonstrates how tube innovation can involve advances in additive chemistry rather than only changes to container material or dimensions. The commercial relevance will depend on laboratory validation, compatibility with established analytical methods, and the ability to demonstrate consistent performance across different sample conditions.
Other development priorities include improving tube materials, closure security, additive stability, labeling, and compatibility with automated laboratory systems. Plastic Tube designs may be refined to maintain consistent dimensions and reduce the risk of breakage during transport and processing, while Glass Tube development can focus on controlled manufacturing tolerances and secure packaging for applications where glass remains preferred. Manufacturers are also working to make product identification clearer through barcode labels, standardized color coding, and updated electronic instructions for use. Research-oriented collection formats are extending the concept of the blood collection tube into specialized sample preservation. For example, OraSure's HEMAcollect-PROTEIN, launched in July 2025 for research use, was designed to stabilize plasma proteins in whole blood for up to 7 days under specified conditions. Although it is not a routine clinical diagnostic tube, it illustrates the scope for differentiated specimen-stabilization technologies.
Five Recent Developments
- January 2024 – FDA clearance for BD Vacutainer Fluoride Tubes: The U.S. FDA issued a substantial-equivalence decision for BD Vacutainer Fluoride Blood Collection Tubes on January 19, 2024. The regulatory milestone supported continued commercialization of a tube category used in clinical chemistry workflows where fluoride-based additives help manage glucose specimen requirements.
- March 2024 – BD updates its SST product portfolio: BD communicated changes to the intended use, electronic instructions for use, labeling, and product array for its Vacutainer Serum Separator Tubes. The update included a 10.0 mL alternative configuration, which became available for ordering in September 2024.
- October 2024 – FDA decision for BD citrate collection tubes: The FDA issued a substantial-equivalence decision for BD Vacutainer Citrate Blood Collection Tubes on October 31, 2024. Citrate tubes are used in coagulation testing workflows, where appropriate blood-to-additive ratios and consistent fill performance are important to specimen reliability.
- July 2025 – OraSure launches HEMAcollect-PROTEIN: OraSure Technologies announced the launch of HEMAcollect-PROTEIN on July 10, 2025, through its DNA Genotek subsidiary. The evacuated collection tube was developed for proteomic research and designed to stabilize plasma proteins in whole blood for up to 7 days under specified conditions; it was identified as a research-use product rather than a routine diagnostic tube.
- January–February 2026 – Terumo launches VenoJect II RAPClot in Japan: Terumo introduced VenoJect II RAPClot blood collection tubes in the Japanese market using Q-Sera's rapid-serum technology. The product is designed to produce high-quality serum in approximately 5 minutes, including from anticoagulated samples, highlighting a move toward faster specimen preparation.
Report Coverage
This clinical disposable blood collection tube market report evaluates the global industry through 2035, with the supplied market forecast indicating a 2.2% CAGR over 2026–2035. The product analysis is restricted to the two specified material categories: Plastic Tube and Glass Tube. For 2026, Plastic Tube is estimated to account for 63% of the market, while Glass Tube represents 37%, bringing the combined product share to exactly 100%. The application assessment covers Medical Center and Blood Center. Medical Center is estimated to contribute 76% of demand, compared with 24% for Blood Center, also totaling exactly 100%. The report examines the influence of diagnostic testing volumes, chronic disease monitoring, laboratory automation, specimen integrity, material selection, regulatory requirements, and supply-chain performance on demand across these categories.
The geographic assessment covers Asia-Pacific, North America, Europe, Latin America, and the Middle East & Africa. Their estimated 2026 market shares are 36%, 27%, 24%, 7%, and 6%, respectively, producing a verified combined regional share of exactly 100%. Asia-Pacific is identified as the leading region and is projected to record the fastest regional growth, with an indicative 3.1% CAGR through 2035. The competitive review includes Sarstedt, TUD, Hongyu Medical, Medtronic, BD, Sanli, GBO, Terumo, Gong Dong, and CDRIC. It considers product portfolio development, manufacturing quality, regulatory activity, distribution capabilities, and innovation in specimen preservation. Company-level market shares are not assigned where comparable verified figures are unavailable, ensuring that the competitive assessment distinguishes established market participation from unsupported numerical claims.
| REPORT COVERAGE | DETAILS |
|---|---|
|
Market Size Value In |
US$ 125954.33 Million in 2026 |
|
Market Size Value By |
US$ 184740.94 Million by 2035 |
|
Growth Rate |
CAGR of 2.2 % from 2026 to 2035 |
|
Forecast Period |
2026 to 2035 |
|
Base Year |
2025 |
|
Historical Data Available |
2021-2024 |
|
Regional Scope |
Global |
|
Segments Covered |
Type and Application |
Related Reports
-
What will be the projected value of Clinical Disposable Blood Collection Tube Market by 2035?
The Clinical Disposable Blood Collection Tube Market is projected to reach USD 184740.94 Million by 2035, expanding at a steady pace during the forecast period. Market growth is supported by rising demand, technological advancements, and increasing adoption across major end-use industries worldwide.
-
What is the expected CAGR of the Clinical Disposable Blood Collection Tube Market during 2026-2035?
The Clinical Disposable Blood Collection Tube Market is expected to grow at a CAGR of 2.2% during the forecast period from 2026 to 2035.
-
Which companies are leading the Clinical Disposable Blood Collection Tube Market?
Key players in the Clinical Disposable Blood Collection Tube Market market include Sarstedt, TUD, Hongyu Medical, Medtronic, BD, Sanli, GBO, Terumo, Gong Dong, CDRIC
-
How large was the Clinical Disposable Blood Collection Tube Market in 2025?
The Clinical Disposable Blood Collection Tube Market was valued at USD 123242.98 Million in 2025, reflecting strong demand and continued adoption across major industries.